Thursday, August 08, 2013 11:04:57 AM
If:
a) You believe that MNTA has successfully characterized Copaxone and;
b) You believe that FTA approval will occur sometime before the expiration of TEVA's patents.
Then:
c) There is a strong possibility that the stock will appreciate significantly on the announcement in b). Why would I sell now just as the Copaxone story is most likely about to begin? (And I believe that, given that MYL submitted its ANDA 14 months after MNTA and they just repurposed a generic that already exists, that MNTA will probably have decent revenues for quite some time after aapproval.)
FEATURED Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
